Novozymes A/S

Novozymes A/S

NVZMF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$30.82B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Novozymes A/SNovozymes A/S40.91.44%-2%7.30.3

Earnings Call Q3 2026

November 5, 2026 - AI Summary

Strong top-line and margin performance in 1–9M 2026 (with pricing/synergies key) - Organic sales growth: +7% in the first 9 months (≈ +2.0pp pricing, +1.0pp sales synergies), with ~1pp headwind from exiting certain countries. - Adjusted EBITDA margin: 37.9% (+60 bps YoY). Q3 margin 38.3% (+120 bps YoY) driven by sales leverage. - Cash generation: Operating cash flow EUR 898m (+1% YoY). Free cash flow before acquisitions: EUR 557.1m (17% of sales), down EUR 111m YoY mainly due to temporary higher investment level / working capital effects.
2026 guidance reiterated; Q4 expected to stay solid - Full-year organic sales growth: 7%–8% (unchanged), expected to be mainly volume-driven, with ~+1pp synergies and ~+1.5pp pricing. - Q4 organic growth: high-single digit. - EBITDA margin: expected at the higher end of 37%–38% (slightly currency-negative at current FX). - Included headwinds/one-offs: ~1pp negative from exiting countries; Q1 had an inventory buildup tailwind in Animal that is expected to be neutral over the year; U.S. tariff refunds slightly impacting 2H.
Portfolio resilience + innovation engine (good surprise: pipeline keeps accelerating) - Geographic balance: Developed markets +7%, emerging +6% organically. - Innovation: 18 new wire solutions launched in 9M, on track for 30+ for the full year (positioned as supporting healthier/better products, yield, and resilient/efficient production). - M&A / technology expansion: Completed acquisition of the remaining shares of MicroBioGen (minority since 2013) on Oct 1—strengthens yeast platform (biofuels today, broader opportunities ahead).

Exclusive for Stockcircle Pro members

Sign upSign Up
$0.81

Current Fair Value

98.8% downside

Overvalued by 98.8% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$30.82 Billion
Enterprise Value$33.25 Billion
Annual dividend$1.02
Dividend yield1.44%
Earnings per Share$1.25
Beta0.62
Outstanding Shares469,750,000

Return

Return on Equity-1.81%ROE
Return on Assets-1.21%
Return on Invested Capital6.50%

Valuation & Multiples

P/E Ratio40.92P/E Ratio
PEG111.42PEG
Price to Sales7.29Price to Sales
Price to Book Ratio2.85Price to Book Ratio
Enterprise Value to Revenue7.58
Enterprise Value to EBIT33.36
Enterprise Value to Net Income-164
Total Debt to Enterprise0.09
Debt to Equity0.26Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
$0.61
Est. $0.75
Revenue
$1.29 B
Est. $1.29 B

Next Earnings Call

Expected Date
February 11, 2027
EPS Estimate
$0.64
Consensus analyst estimate
Revenue Estimate
$1.21 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Novozymes A/S

11,098 employees
CEO: Ester Baiget

Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends ...